Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4131 | 1766 | 44.3 | 92% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
532 | 14062 | TOLL LIKE RECEPTOR//TOLL LIKE RECEPTORS//CD14 |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CPG ODN | Author keyword | 120 | 52% | 9% | 161 |
2 | CPG MOTIF | Author keyword | 71 | 66% | 4% | 66 |
3 | CPG DNA | Author keyword | 70 | 54% | 5% | 90 |
4 | CPG OLIGODEOXYNUCLEOTIDES | Author keyword | 43 | 60% | 3% | 47 |
5 | SECT RETROVIRAL IMMUNOL | Address | 34 | 61% | 2% | 36 |
6 | TLR9 | Author keyword | 33 | 29% | 5% | 95 |
7 | CPG OLIGODEOXYNUCLEOTIDE | Author keyword | 30 | 59% | 2% | 34 |
8 | CPG MOTIFS | Author keyword | 25 | 46% | 2% | 40 |
9 | CPG | Author keyword | 21 | 18% | 6% | 110 |
10 | IMMUNOSTIMULATORY DNA | Author keyword | 21 | 75% | 1% | 15 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CPG ODN | 120 | 52% | 9% | 161 | Search CPG+ODN | Search CPG+ODN |
2 | CPG MOTIF | 71 | 66% | 4% | 66 | Search CPG+MOTIF | Search CPG+MOTIF |
3 | CPG DNA | 70 | 54% | 5% | 90 | Search CPG+DNA | Search CPG+DNA |
4 | CPG OLIGODEOXYNUCLEOTIDES | 43 | 60% | 3% | 47 | Search CPG+OLIGODEOXYNUCLEOTIDES | Search CPG+OLIGODEOXYNUCLEOTIDES |
5 | TLR9 | 33 | 29% | 5% | 95 | Search TLR9 | Search TLR9 |
6 | CPG OLIGODEOXYNUCLEOTIDE | 30 | 59% | 2% | 34 | Search CPG+OLIGODEOXYNUCLEOTIDE | Search CPG+OLIGODEOXYNUCLEOTIDE |
7 | CPG MOTIFS | 25 | 46% | 2% | 40 | Search CPG+MOTIFS | Search CPG+MOTIFS |
8 | CPG | 21 | 18% | 6% | 110 | Search CPG | Search CPG |
9 | IMMUNOSTIMULATORY DNA | 21 | 75% | 1% | 15 | Search IMMUNOSTIMULATORY+DNA | Search IMMUNOSTIMULATORY+DNA |
10 | TOLL LIKE RECEPTOR 9 | 19 | 29% | 3% | 56 | Search TOLL+LIKE+RECEPTOR+9 | Search TOLL+LIKE+RECEPTOR+9 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BACTERIAL DNA | 584 | 44% | 58% | 1017 |
2 | IMMUNOSTIMULATORY DNA | 151 | 54% | 11% | 194 |
3 | DEOXYRIBONUCLEIC ACID FRACTION | 117 | 79% | 4% | 75 |
4 | CONTAINING OLIGODEOXYNUCLEOTIDES | 69 | 93% | 1% | 26 |
5 | CPG MOTIFS | 53 | 26% | 10% | 174 |
6 | INDUCED IMMUNE ACTIVATION | 50 | 77% | 2% | 34 |
7 | TOLL LIKE RECEPTOR 9 | 50 | 33% | 7% | 125 |
8 | SYNTHETIC OLIGONUCLEOTIDES | 35 | 32% | 5% | 92 |
9 | OLIGODEOXYNUCLEOTIDES | 35 | 12% | 16% | 285 |
10 | IMMUNOSTIMULATORY DNA SEQUENCES | 34 | 49% | 3% | 51 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Therapeutic potential of Toll-like receptor 9 activation | 2006 | 575 | 189 | 66% |
Exon skipping therapy for Duchenne muscular dystrophy | 2015 | 1 | 1 | 100% |
CpG DNA as a vaccine adjuvant | 2011 | 124 | 134 | 62% |
CpG motifs in bacterial DNA and their immune effects | 2002 | 1545 | 272 | 62% |
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists | 2009 | 183 | 174 | 64% |
CpG Still Rocks! Update on an Accidental Drug | 2012 | 52 | 102 | 62% |
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer | 2008 | 142 | 34 | 62% |
Development of TLR9 agonists for cancer therapy | 2007 | 211 | 113 | 44% |
Use of CpG oligonucleotides in treatment of asthma and allergic disease | 2009 | 67 | 39 | 74% |
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists | 2007 | 414 | 86 | 19% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SECT RETROVIRAL IMMUNOL | 34 | 61% | 2.0% | 36 |
2 | SECT RETROVIRAL | 21 | 85% | 0.6% | 11 |
3 | BIOPHARMACEUT DRUG METAB | 7 | 20% | 1.7% | 30 |
4 | SAM ROSE STEIN AGING | 5 | 16% | 1.8% | 31 |
5 | SECT RADIAT MED | 4 | 75% | 0.2% | 3 |
6 | RETROVIRAL IMMUNOL SECT | 2 | 36% | 0.3% | 5 |
7 | BIOCONTROL ENGN GRASSLAND PESTS | 2 | 67% | 0.1% | 2 |
8 | BIONICHE THER EUT | 2 | 67% | 0.1% | 2 |
9 | INTERDISCIPLINARY IMMUNOL PROGRAM | 2 | 17% | 0.7% | 12 |
10 | UP 264 | 2 | 40% | 0.2% | 4 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000190145 | UNC93B1//MARY KIRKLAND LUPUS//TLR7 |
2 | 0.0000127819 | TOLL LIKE RECEPTOR 9//TOLL LIKE RECEPTOR 3//95D CELL |
3 | 0.0000096996 | PLASMACYTOID DENDRITIC CELLS//BDCA 4//PLASMACYTOID DENDRITIC CELL |
4 | 0.0000092477 | DNA VACCINE//DNA VACCINES//DNA IMMUNIZATION |
5 | 0.0000073103 | HETEROPHILS//HETEROPHIL//SECT AVIAN VIROL BIOTECHNOL |
6 | 0.0000066415 | VACCINE DELIVERY//PLG MICROPARTICLES//ADJUVANT UNIT |
7 | 0.0000064665 | TL 2 RESPONSE//ADCC REACTION//ANTI IG DEXTRAN |
8 | 0.0000061722 | TIR DOMAIN//PELLINO//INNATE IMMUN INFLAMMAT |
9 | 0.0000060129 | ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT//ANTISENSE RESEARCH AND DEVELOPMENT//ANTISENSE |
10 | 0.0000056219 | INNATE IMMUNITY OF THE SKIN//PERMAFROST MICROORGANISMS//TYUMEN |